Osteoarthritis (OA) is a painful, degenerative condition that is characterized by the gradual development of joint pain, as well as joint stiffness and limitation of movement in the joints. Of these symptoms, the chief complaint among individuals with OA is pain, which we estimate affected nearly 65 million individuals in the United States and Europe in 2016. Despite multiple available therapies spanning several drug classes, no truly novel therapies effective at treating OA pain have launched in more than a decade, and existing analgesics’ efficacy and/or safety and tolerability profiles leave room for improvement.

Questions Answered:

  • What are the main treatment drivers and goals for OA pain?
  • What are surveyed rheumatologists’ opinions of the relative performance of select therapies, including celecoxib (Pfizer’s Celebrex, generics) and Vivlodex (Iroko), on key efficacy, safety/tolerability, and convenience of administration attributes related to OA pain?
  • Which clinical attributes are key influencers of physician prescribing decisions, which have limited impact, and which are hidden opportunities?
  • What trade-offs in price and drug performance across select clinical attributes are acceptable to U.S. and European rheumatologists for a hypothetical new OA pain drug?

Product Description

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Table of contents

  • Osteoarthritic Pain - Unmet Need - Detailed, Expanded Analysis (US/EU)
    • Treatment Drivers and Goals
      • Overview
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Physician Rating of Treatment Drivers and Goals in OA Pain
        • Importance of Efficacy Attributes to Prescribing Decisions in OA Pain: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in OA Pain: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in OA Pain: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in OA Pain: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in OA Pain: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in OA Pain: Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in OA Pain: United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in OA Pain: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for OA Pain
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for OA Pain: United States
        • Overall Performance of Key Therapies for OA Pain: Europe
        • Relative Performance of Key Therapies for OA Pain Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for OA Pain Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for OA Pain Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for OA Pain Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for OA Pain Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for OA Pain Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Rheumatologists’ Satisfaction with the Performance of Key Therapies for OA Pain on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Rheumatologists’ Satisfaction with the Performance of Key Therapies for OA Pain on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Physician Rating of Unmet Need in OA Pain
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in OA Pain: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in OA Pain: Europe
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in OA Pain: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in OA Pain: Europe
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in OA Pain: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in OA Pain: Europe
      • Unmet Need in OA Pain and Related Indications
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need in OA Pain and Related Indications: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need in OA Pain and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the OA Pain Market and Emerging Therapy Insights
        • Opportunity: Therapy with Superior Efficacy to NSAIDs for Reducing OA Pain Intensity
        • Opportunity: Therapy That Slows Joint Deterioration and Better Improves Physical Functioning
        • Opportunity: A Therapy with the Analgesic Efficacy of an Opioid Without the Risk for Tolerance and Abuse
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
        • Assigned Prohibitions for the Conjoint Module
      • Attribute Importance and Part-Worth Utilities
        • OA Pain Target Product Profile: Attribute Importance
        • Reduction from Baseline in WOMAC Pain Score (12 Weeks) vs. Placebo
        • % Patients with ≥ 50% Decrease in Pain Intensity from Baseline (12 Weeks) vs. Placebo
        • Reduction from Baseline in PGAAP Score (6 Weeks) vs. Placebo
        • % Patients Experiencing Abuse
        • % Patients Experiencing GI Side Effects vs. Placebo
        • Delivery Profile
        • Price Per Treated Day
      • Conjoint-Analysis-Based Simulations of Market Scenarios
        • OA Pain Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • OA Pain Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • OA Pain Market Simulations: Target Product Profiles Included in Scenario 1
        • OA Pain Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • OA Pain Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • OA Pain Market Simulations: Target Product Profiles Included in Scenario 2
        • OA Pain Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 3
        • OA Pain Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 3
        • OA Pain Market Simulations: Target Product Profiles Included in Scenario 3
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Natalie Taylor, Ph.D.; Ankuri Setia, B.D.S., P.G.D.H.M.

Natalie Taylor, Ph.D., is a principal business insights analyst on the CNS/Ophthalmology Disorders team at DRG, part of Clarivate. She has more than ten years of experience authoring primary and market research reports for pharmaceutical industry clients in the fields of psychiatry, pain, neurology, and ophthalmology. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of its CNS portfolio. She completed her Ph.D. in physiology at Dartmouth College in New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in biology from Dickinson College in Pennsylvania.

Ankuri Setia, B.D.S., P.G.D.H.M., is an analyst on the CNS team at DRG, part of Clarivate. She earned a master's degree in healthcare management from the Institute of Health Management Research.


Related Reports

Osteoarthritic Pain - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of osteoarthritis (OA) pain comprises epidemiological estimates of key patient po...

View Details

Osteoarthritis - Epidemiology - Americas

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 coun...

View Details

Osteoarthritis - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 coun...

View Details